Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited provided earnings guidance for the six months ended June 30, 2025. It is estimated that the net profit attributable to equity holders of the parent for the six (6) months ended 30 June 2025 ("1H FY2025") will range from approximately RMB 1,840 million to RMB 2,000 million. This represents an increase of approximately RMB 1,182.28 million to RMB 1,342.28 million compared to the corresponding period ended 30 June 2024 ("1H FY2024"), reflecting a year-on-year increase of approximately 180% to 204%.
It is estimated that the net profit attributable to equity holders of the parent (after deducting non- recurring gains or losses) for 1H FY2025 will range from approximately RMB 560 million to RMB 620 million. This represents a decrease of approximately RMB 73.83 million to RMB 13.83 million compared to 1H FY2024, reflecting a year-on-year decrease of approximately 12% to 2%.
